Century Therapeutics Inc (IPSC) Stock Price, Quote & News

Company Profile

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 817 5790

Website: www.centurytx.com

Address:

25 North 38th Street, 11th Floor, Philadelphia, United States

NVDAMillionaire Jul. 24 at 11:58 PM

$IPSC Excellent article that nails exactly where IPSC stands right now. So if you want to update your IPSC knowledge or get acquainted with IPSC, this is a must read. https://beyondspx.com/article/unpacking-century-therapeutics-strategic-shift-and-cash-runway-post-bmy-ipsc

0 · Reply

Beast2025 Jul. 24 at 7:47 PM

$IPSC AH $7

0 · Reply

Dusty_Bunz Jul. 23 at 3:27 PM

$IPSC Im taking it

0 · Reply

Dusty_Bunz Jul. 17 at 2:23 PM

$IPSC In here .58

0 · Reply

Dusty_Bunz Jul. 17 at 4:16 AM

$IPSC 👀

0 · Reply

biochirp Jul. 14 at 3:01 PM

$IPSC why isn’t the board shutting this down, it’s a failed science experiment time to move on

1 · Reply

Ned_Nosurname Jul. 14 at 4:35 AM

$IPSC They also hinted at plans to sell up to $200 million in securities in a separate SEC filing https://investors.centurytx.com/static-files/468565ae-ed58-4a22-bae9-18ae3692880b

0 · Reply

biochirp Jul. 11 at 5:37 PM

$IPSC SHUT IT DOWN

0 · Reply

OnlyFibs Jul. 11 at 12:47 AM

$IPSC - im not a penny guy but volume and charts dont lie, lets run this to .95 and see how volume reacts? #hovdid

0 · Reply

biochirp Jul. 10 at 7:36 PM

$IPSC market cap 53M, cash >150M, 3X on return to shareholders make it happen

0 · Reply

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 15, 2025, 4:01 PM EDT - 2 months ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:30 PM EDT - 3 months ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Mar 19, 2025, 4:01 PM EDT - 4 months ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Nov 26, 2024, 7:00 AM EST - 8 months ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:05 AM EST - 9 months ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 7:00 AM EST - 9 months ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Sep 26, 2024, 7:00 AM EDT - 10 months ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 20, 2024, 11:07 AM EDT - 1 year ago

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 6:03 PM EST - 1 year ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 1, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 9, 2023, 12:00 PM EST - 1 year ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 6, 2023, 7:30 AM EST - 1 year ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

$Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus$

Dec 6, 2023, 7:30 AM EST - 1 year ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Nov 21, 2023, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 9, 2023, 7:01 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 1 year ago

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Aug 9, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Century Therapeutics Announces Leadership Changes

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Century Therapeutics to Present at the AACR Annual Meeting 2023

Feb 21, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at Upcoming Investor Conferences

$Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas$

Feb 8, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE TECH

Jan 10, 2023, 7:33 AM EST - 2 years ago

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

FATE THRD VERA

Jan 9, 2023, 9:06 PM EST - 2 years ago

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Jan 5, 2023, 4:01 PM EST - 2 years ago

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

Jan 4, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 11, 2022, 7:00 AM EST - 2 years ago

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Nov 10, 2022, 7:30 AM EST - 2 years ago

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 2, 2022, 7:05 AM EDT - 2 years ago

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Century Therapeutics to Present at the SITC 37th Annual Meeting

Oct 3, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 25, 2022, 7:30 AM EDT - 3 years ago

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

Aug 11, 2022, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Jun 24, 2022, 4:30 PM EDT - 3 years ago

Century Therapeutics Announces Its Addition to the Russell Microcap® Index

NVDAMillionaire Jul. 24 at 11:58 PM

0 · Reply

Beast2025 Jul. 24 at 7:47 PM

$IPSC AH $7

0 · Reply

Dusty_Bunz Jul. 23 at 3:27 PM

$IPSC Im taking it

0 · Reply

Dusty_Bunz Jul. 17 at 2:23 PM

$IPSC In here .58

0 · Reply

Dusty_Bunz Jul. 17 at 4:16 AM

$IPSC 👀

0 · Reply

biochirp Jul. 14 at 3:01 PM

$IPSC why isn’t the board shutting this down, it’s a failed science experiment time to move on

1 · Reply

Ned_Nosurname Jul. 14 at 4:35 AM

$IPSC They also hinted at plans to sell up to $200 million in securities in a separate SEC filing https://investors.centurytx.com/static-files/468565ae-ed58-4a22-bae9-18ae3692880b

0 · Reply

biochirp Jul. 11 at 5:37 PM

$IPSC SHUT IT DOWN

0 · Reply

OnlyFibs Jul. 11 at 12:47 AM

$IPSC - im not a penny guy but volume and charts dont lie, lets run this to .95 and see how volume reacts? #hovdid

0 · Reply

biochirp Jul. 10 at 7:36 PM

$IPSC market cap 53M, cash >150M, 3X on return to shareholders make it happen

0 · Reply

Rage_Against_The_Machine Jul. 7 at 8:15 PM

$IPSC slashes 51% of workforce in survival move - CFO & Chief Development Officer out. $3.7M severance costs now, but cash reserves ($51.8M) still face <6 quarter runway. Restructuring desperation or smart preservation? Market's 0.197 P/B ratio screams skepticism. https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/tm2519717d1_8k.htm

1 · Reply

revueltoL Jul. 3 at 11:34 AM

$IPSC good time to add 👇

0 · Reply

ClenchFists Jul. 2 at 4:59 PM

$IPSC Loading! Here we gooooo

0 · Reply

dukyboa Jul. 2 at 3:35 PM

$IPSC Thinking this might be a good swing towards next earnings... Crazy surprise last earnings call and company flipped profitable. If next earnings are similar might finally see some good action.

0 · Reply

ka1954 Jun. 27 at 11:22 PM

$ACRV $GBIO $IPSC $XFOR why am i seeing so many stocks dumping right before close? GBIO, ACRV, IPSC

2 · Reply

biochirp Jun. 25 at 2:47 PM

$IPSC shut down and return cash to shareholders NOW!!

0 · Reply

RedTex_ Jun. 24 at 4:57 PM

$MULN $YYAI $HBIO $IPSC This guy is a pump and dump fiend. Please report him for cross posting naked lies. He does this every day. 👇$NMRA $DVLT

1 · Reply

Profitier Jun. 24 at 2:48 PM

$IPSC Still adding..

0 · Reply

Profitier Jun. 20 at 4:00 PM

$IPSC Numerous employees just got stock options to buy @.6, that typically means the company is expecting the stock price to be well above that giving their employees the benefit of buying cheaper.. Huge current insider ownership as well$$ https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001850119&type=&dateb=&owner=include&count=40&search_text=

0 · Reply

Ned_Nosurname Jun. 17 at 12:19 AM

$IPSC The posters https://www.centurytx.com/wp-content/uploads/EULAR-2025-alpha-beta-CAR-T-cells.pdf https://www.centurytx.com/wp-content/uploads/EULAR-2025-CNTY-101.pdf

0 · Reply

Sn1perWolf Jun. 16 at 10:50 AM

$IPSC

0 · Reply

Profitier Jun. 11 at 9:31 PM

$IPSC Good stuff - https://x.com/biomedicalrx/status/1932895251376844853?s=46

0 · Reply

Market Cap	53.90M
Revenue (ttm)	6.59M
Net Income (ttm)	-126.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,920.64%
Debt to Equity Ratio	0.00

Volume	1,200,900
Avg Vol	983,746
Day's Range	N/A - N/A
Shares Out	86.16M
Stochastic %K	56%
Beta	1.78
Analysts	Strong Sell
Price Target	$4.40